Homepage
Videos
Dr. Stephen Chan and Dr. Madhukar Trivedi explore the role of neuroplasticity in MDD and how neuroplasticity can be impacted by emerging digital therapeutics for the treatment of major depressive disorder.
News
Participate in this quiz on major depressive disorder and chronicity of symptoms.
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating major depressive disorder (MDD), according to a study in the Journal of Affective Disorders.
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with transcranial magnetic stimulation (TMS) compared with other patients, according to a study published in Nature Mental Health that was carried out in collaboration with the National Veterans Administration (VA).
Antidepressant prescribing patterns and outcomes for patients with major depressive disorder (MDD) vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and prolonged grief disorder (PGD) appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close oth
Education
This activity focuses on optimizing the management of major depressive disorder (MDD) by addressing residual symptoms and side effects associated with conventional antidepressants. Participants will review the latest data on precision serotonin receptor modulators, their mechanisms of action, and strategies for antidepressant selection and switching to enhance outcomes through shared decision-making and collaborative care.
This activity examines the significant burden of anhedonia in major depressive disorder (MDD), highlighting its impact and the limitations of traditional treatments. Participants will explore the neurobiological underpinnings and emerging precision treatments for anhedonia, while learning to implement patient-centered strategies to assess and optimize its management.
This educational activity explores the use of atypical antipsychotics (AAPs) in treating depressive episodes, focusing on differentiating bipolar depression (BD) from major depressive disorder (MDD) to enhance diagnostic accuracy. Participants will gain insights into the challenges of managing these conditions, review FDA-approved AAPs' mechanisms, efficacy, and safety, and develop strategies for effective treatment implementation.
Posters
Traditional antidepressant monotherapies are associated with poor outcomes in patients with impaired symptom domains of anhedonia and interest-activity. AXS-05 (dextromethorphan-bupropion; AUVELITY) is a novel, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved in the US for treatment of major depressive disorder (MDD) in adults.
This study examined whether an online CME clinical demonstration module can improve learners’ self-reported clinical behaviors related to management of MDD, identifying patients who may benefit from pharmacogenomic testing (PGx), interpreting the results and incorporating data into clinical decision-making, communicating benefits and limitations of PGx to patients.
Anhedonia is a core symptom of major depressive disorder (MDD). However, there is a lack of understanding of the healthcare and humanistic burden associated with prominent anhedonia in patients with MDD.
The Pathway Platform was designed to enhance patient-provider engagement and encourage use of outcome measures for major depressive disorder (MDD) to improve adherence to measurement-based care (MBC) in primary care. This post hoc subgroup analysis of the Pathway Platform implementation study examined the effect of antidepressant (AD) changes on outcomes.
Anhedonia is a key symptom of Major Depressive Disorder (MDD), however, there is limited knowledge about the impact of prominent anhedonia on clinical improvement and treatment satisfaction in patients diagnosed with MDD.